Polycythemia Vera (PV) and Essential Thrombocythemia (ET) are chronic myeloproliferative neoplasms associated with thrombotic and/or hemorrhagic complications, and increased risk of transformation to myelofibrosis and acute myeloid leukemia. The main goal of therapy is aimed at preventing vascular events that are the leading cause of morbidity and mortality in these patients. Accordingly, risk stratification is the basis for deciding when to treat a patient with cytoreductive therapy. The European LeukemiaNet has developed a series of management recommendations for front-line and second-line therapy in order to provide the optimal treatment for the individual patient. There is still controversy about the efficacy and safety of several modalities of cytoreductive treatment at the long-term in both diseases as well as in the use of antiplatelet therapy in ET. The presence of JAK2V617F and CALR mutations in ET patients has been related to different thrombotic risk and this fact will probably lead to different therapeutic approaches in a near future. On the other hand, the near normal life expectancy of these patients makes essential a careful analysis of benefits and risks associated to treatment. This review provides our current management strategy of PV and ET patients.
Introduction
Essential thrombocythemia (ET) and polycythemia vera (PV) are classic BCR-ABL1-negative myeloproliferative neoplasms (MPN) characterized by overproduction of mature blood cells, an increased risk of thrombosis and/or hemorrhage, and a tendency to transform to myelofibrosis and acute leukemia 1 . Both ET and PV are the most common BCR-ABL1-negative MPN and the life expectancy of these patients is only slightly reduced 2 . This fact, together with the relatively low incidence of thrombotic complications, and the remarkable proportion of young patients with ET determine a careful analysis of benefits and risks associated to treatment.
In the present review, I will discuss the different modalities of treatment based in a riskadapted approach, the rationale of the use of the current options, and some personal views based in my clinical experience.
Goals of therapy
The goals of therapy in ET and PV are similar, including prevention of occurrence and/or recurrence of thrombotic and bleeding complications, control of disease-related symptoms, decrease of the risk of transformation to acute leukemia and myelofibrosis, and management of certain risk situations such as pregnancy and surgery 3 .
Thrombotic and hemorrhagic complications are the main causes of morbidity and mortality in PV and ET 4, 5 . Transformation to myelofibrosis may form part of the natural history of the disease and acute transformation is generally related to the sequential use of chemotherapy 6 . Unfortunately, although we can reasonably decrease the risk of vascular complications applying treatment based on consensus recommendations, conventional therapies are not able, at present, of decreasing or modifying the risk of transformation to myelofibrosis.
Risk-adapted treatment approach
In PV, the classical or conventional stratification system is based on thrombotic risk and divides patients into high-risk and low-risk categories. Advanced age (> 60 years) and/or history of thrombosis are the two main clinical variables predictive of the appearance of thrombotic complications. Thus, the existence of at least one of them assigns the patient into the high-risk group, indicating the need for starting cytoreductive therapy 3 . This clinical approach is a pragmatic and easy classification that allows deciding, once the diagnosis has been established, to start cytoreductive therapy.
Regarding ET, most clinicians use the same risk stratification system than in PV to allocate the patient to a risk category of thrombosis. A new prognostic system has been developed to refine this classical stratification system. The IPSET (International Prognostic Score in WHO-ET)-thrombosis model incorporates some clinical and biological variables such as cardiovascular risk factors and the presence of the JAK2V617F mutation. According to this system, three risk categories are defined with different thrombosis risk rates (per patients/year) 7 (Table 1) . Recent studies have
shown that calreticulin (CALR)-mutated ET patients present a lower risk of thrombosis when compared to JAK2V617F-mutated ET patients 8, 9 . In spite of the fact that the mutational status of CALR gene does not impact on the IPSET-thrombosis prognostic score 10 , probably the observed lower rate of thrombosis associated to CALR mutation will modify in a near future our current strategy of treatment of patients with ET. In addition to the IPSET-thrombosis score, an IPSET-survival model has also been generated including leukocyte count >11x10 9 /L as a biological parameter beside advanced age and history of thrombosis 11 (Table 1) . Both IPSET prognostic systems have been established from retrospective data, so they need to be validated in prospective clinical studies before being accepted as clinical-decision treatment tools.
In my clinical practice, the decision to start cytoreductive therapy in the individual patient is based on the conventional stratification system both for ET and PV. . The MPN-SAF TSS is a specific symptom burden questionnaire developed and validated in many languages to assess the patient's perception of common symptoms and overall quality of life on a 0 (absent) to 10 (worst imaginable) scales. The symptoms include fatigue, concentration problems, early satiety, inactivity, night sweats, itching, abdominal discomfort, bone pain, weight loss, and fever. This questionnaire is a useful tool to monitor symptom burden and quality of life either at diagnosis or during clinical evolution and should be incorporated into routine clinical practice 15 .
Antiplatelet therapy in PV and ET
The use of daily low-dose (75/100 mg) acetylsalicylic acid (ASA) as primary prophylaxis of thrombosis is recommended for all PV patients. The ECLAP study included a total of 518 PV patients in a double-blind, placebo-controlled, randomized trial to assess the safety and efficacy of prophylaxis with low-dose aspirin. The two primary end points were the cumulative rate of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes and the cumulative rate of nonfatal myocardial infarction, nonfatal stroke, pulmonary embolism, major venous thrombosis, or death from cardiovascular causes. Low-dose ASA, compared with placebo, was associated with a 50% to 60% reduction in the risk of nonfatal myocardial infarction, nonfatal stroke, pulmonary embolism, major venous thrombosis, or death from cardiovascular causes. In addition, the incidence of major bleeding episodes was not significantly increased in the aspirin group 16 . According to these data, most clinicians recommend low-dose ASA in PV patients who have no contraindications for antiplatelet therapy.
A general practice among clinicians involved in the care of ET patients is to prescribe low-dose ASA irrespective of the risk category. This empiric approach is mainly based in the extrapolation of results from the ECLAP study and in the efficacy of ASA in controlling microvascular symptoms. However, the effectiveness of low-dose ASA in the primary prevention of thrombosis in ET patients has not been assessed in prospective randomized clinical trials and some uncertainties encompass this clinical practice 17 .
In order to study whether primary prophylaxis with low-dose ASA plus cytoreduction benefits patients with high-risk ET, the incidence of thrombosis and hemorrhage in 247 patients during the periods of time in which they received combination therapy (cytoreduction+low-dose ASA) or cytoreduction alone as primary prophylaxis of thrombosis was analyzed retrospectively. Patients who had a history of previous thrombosis were excluded from the study. In the subgroup of patients in whom the indication of cytoreduction was age older than 60 years, the addition of low-dose ASA resulted in a lower incidence of thrombosis (0.86 events per 100 person-years) than under cytoreduction alone (2.9 events per 100 person-years). Although the addition of low-dose ASA significantly increased the incidence of bleeding, this increase was much lower than the benefit obtained in thrombosis reduction. Moreover, the interaction analysis showed that among patients older than 60 years, low-dose aspirin yielded the greatest benefit in those patients with cardiovascular risk factors or the JAK2V617F mutation 18 . The conclusion of this study was that low-dose aspirin benefits high-risk ET patients older than 60 years receiving cytoreductive therapy as primary prophylaxis of thrombosis.
The use of low-dose ASA in low-risk ET patients is a matter of debate, given the excessive risk of bleeding observed in patients with extreme thrombocytosis mostly A retrospective study of 300 low-risk ET patients (age <60 years) without thrombosis history showed that the incidence of thrombosis was similar whether they received antiplatelet therapy or not. Of note, the risk of bleeding was five times greater in patients with a platelet count at diagnosis >1000x10 The role of antiplatelet and anticoagulant treatment as secondary prophylaxis in patients with history of thrombosis is not well-defined. Generally, low-dose ASA is advised indefinitely in all patients who have suffered an arterial thrombosis, whereas anticoagulation is recommended for those patients who have presented a venous thrombosis. In the latter case, the duration of oral anticoagulation is established by guidelines recommended for the specific type of thrombosis in the general population.
There is general agreement about the use of lifelong anticoagulation for all these patients (PV or ET) with thrombosis of the intraabdominal veins as well as for those patients who present venous thrombosis recurrences 3 . In a retrospective study of 150 patients with PV and ET treated with vitamin K antagonists (VKA) because of an arterial or venous thrombosis, the incidence of re-thrombosis was 4.5 and 12 per 100 patient-years under VKA therapy and after stopping it, respectively (P<0.0005). After a multivariate adjustment for other prognostic factors, VKA treatment was associated with a 2.8-fold reduction in the risk of thrombotic recurrence. Remarkably, VKA therapy offset the increased risk of re-thrombosis associated with a prior history of remote thrombosis (thrombosis occurring before the two years preceding the MPN diagnosis).
Both the protective effect of VKA therapy and the predisposing factors for recurrence were independent of the anatomical site involved in the first thrombotic event leading to anticoagulant treatment. Treatment periods with VKA did not result in a higher incidence of major bleeding as compared with those without VKA 21 .
The concomitant use of ASA and anticoagulants should be avoided if possible because of the increased risk of bleeding and only can be supported after a very careful and individualized weighing of potential benefits against additional risks.
Management of low-risk patients
In my daily routine I follow the European LeukemiaNet (ELN) recommendations for the treatment of PV (Fig. 2 ). According to these guidelines, the combination of low-dose ASA as primary thromboprophylaxis (discussed previously), control of cardiovascular risk factors and therapeutic phlebotomies is the best approach to manage accurately a low-risk PV patient 3 .
Phlebotomy is a keystone of treatment and the CYTO-PV
Collaborative Group has demonstrated that in patients with PV, those with a hematocrit (Hct) target of less than 45% had a significantly lower rate of cardiovascular death and major thrombosis than did those with a Hct target of 45 to 50% 22 . So, on the basis of this study, a Hct target <45% should be pursued as a standard of care in all patients with PV, irrespective of the risk category to which they belong. Phlebotomies are usually performed by removing 250 to 500 ml of blood every other day or twice a week until the hematocrit target is reached. Generally they are well tolerated, although some patients may complain of the appearance of symptoms of iron deficiency like restless legs syndrome 23 . A practical tip: I always recommend the patient to eat something before the venesection in order to decrease the risk of possible dizziness.
The treatment of low-risk ET patients is similar to the treatment of low-risk PV patients with the exception of phlebotomies. The use of antiplatelet therapy has been discussed in the section of Antiplatelet therapy in PV and ET. In accordance with the recommendations of use of antiplatelet therapy ( Fig. 1) , asymptomatic JAK2V617F-negative low-risk patients without cardiovascular risk factors can be followed by observation alone without the need of a specific therapy. A major clinical dilemma is the degree of thrombocytosis that allows adopting such conservative strategy. In patients <40 years a platelet count >1000x10 9 /L must not be the only criterion to start cytoreduction and even patients with platelet counts between 1000-1500x10 9 /L may benefit from this approach. In such context I recommend to discuss thoroughly the pros and cons, trying to reassure the patient about this conservative strategy. However, there are no solid recommendations in this difficult issue and personal clinical experience is probably the most useful guiding principle.
Management of high-risk patients
Patients with PV at high-risk of thrombosis must be treated with cytoreductive therapy.
In addition to the features defining high-risk, that is, age >60 years and/or history of thrombosis, cytoreductive treatment can be considered, irrespective of the risk category, if the patient presents uncontrolled disease-related symptoms: progressive or symptomatic splenomegaly, severe constitutional symptoms, platelet count >1500x10 9 /L, progressive leukocytosis, and poor tolerance to phlebotomy 3 (Fig. 2) .
The ELN recommends HC and Interferon (IFN) as first-line cytoreductive therapy (Fig.   2 ). The experts also advocate that HC should be used with caution in patients <40
years and that busulfan is a feasible approach for PV patients older than 70 years and I prefer to use busulfan as second line therapy which will be discussed below.
Hydroxycarbamide is an oral antimetabolite usually well tolerated and with a dosedependent action. The recommended starting dose is 15 mg/kg/day (500 mg, twice daily) and then the dose is titrated until achieving normal blood cell counts. In elderly patients I usually start with a lower dose; 500 mg five days and 1000 mg two days per week. A practical approach is to control blood cell count every two weeks during the first two months, every month the following three months, and every three-four months in steady state in responding patients. Macrocytosis and/or a mild macrocytic anemia are frequent. Bone marrow myelosuppression can be observed in some patients. The most common side effects of HC are mostly mucocutaneous as leg ulcers in the perimalleolar area, oral aphtous ulcers, actinic keratosis, and a wide variety of skin lesions 24 . HC has also been associated to an increased risk of skin cancer 25 .
Patients may be afraid or be reluctant to use HC when they read in the patient information leaflet about the potential leukemogenic effect of this drug. Concerning this serious effect, some studies have provided data showing the lack of a strong association between HC and acute leukemia when this drug is used as monotherapy.
In two large cohorts of patients with PV, HC was not statistically associated with an increased risk of acute leukemia when used as a single agent 26, 27 . .
As a result of this study, pipobroman is considered clearly leukemogenic and not suitable for first-line therapy in PV patients. responses, and discontinuation rates ranged between 70% to 91%, 14% to 24%, and 10% to 24%, respectively 31, 32 . Interestingly, in the French cohort 27% of patients could stop PEG-IFN-α2a and remained in complete response without treatment for a median time of 31 months. In addition, no vascular events were reported and in some patients histological complete remission was observed. However, it must be taken into account that overall, 20% to 40% of all patients treated with IFN discontinue therapy by toxicity 33 . A recent report of the updated results of 43 PV and 40 ET patients treated with PEG-IFN-α2a in the MDAnderson Cancer Center has shown that after a median follow-up of 82 months only 39% are still on study (29% on active treatment).
Discontinuation was due not only to nonhematological toxicity but also to vascular events and progression to MF and AL. Of note, at the moment of the analysis most patients were receiving a dose ≤90 mcg every week or every two weeks 34 . A new nextgeneration monopegylated IFN-α2b, ropeginterferon alfa-2b with a longer elimination half-life allows administration every two weeks achieving similar rates of responses (hematologic and molecular) than PEG-IFN-α2a 35, 36 . We still do not know the rate of responses and tolerance as well as the discontinuation rate of this new formulation at the long-term.
Interestingly, concerning molecular responses, PEG-IFN-α2a not only decreases allele burden in JAK2V617F-positive patients but may also decrease CALR mutant allelic burden 37 . In both cases, the presence of additional non-driver mutations, such as TET2 mutations or other mutations may influence the molecular response to treatment Concerning the therapy of high-risk ET, the ELN recommends HC as first-line therapy for all patients, with the same nuances than in PV regarding its use in patients younger than 40 years. Likewise, the use of busulfan is also considered for patients >70 years 3 ( Fig. 3) .
The rationale of current therapeutic strategy in ET is mainly based in the results of randomized trials comparing face to face treatment modalities. In the first historical trial, Cortelazzo et al randomized high-risk ET patients to HC (n=56) or no cytoreductive treatment (n=58). After a median follow-up of 27 months, the rate of thrombotic complications was 3.6% for HC and 24% for those patients assigned to nonmyelosupressive therapy (P=0.003) 39 . The UK-PT1 study randomized 809 high-risk patients diagnosed according to PVSG criteria to HC plus low-dose ASA (n=404) or anagrelide plus low-dose ASA (n=405). With a total observation time of 2,653 patientyears, HC plus ASA was superior to anagrelide plus ASA in terms of reducing the risk of arterial thrombosis, major bleeding and fibrotic progression. Conversely, anagrelide plus ASA was better than HC plus ASA in preventing venous thrombosis. There were no differences between groups in overall survival and death from thrombotic or hemorrhagic cause or from transformation to myelofibrosis. Platelet count was reduced similarly by both drugs at 9 months and afterwards, but the reduction was higher with HC at 3 and 6 months. The rate of drug discontinuation was higher in the anagrelide arm 40 . JAK2V617F-positive patients required lower doses of HC to control their platelet count than JAK2V617F-negative patients, an effect not observed in patients receiving
anagrelide. In addition, JAK2V617F-positive patients receiving anagrelide showed higher rates of arterial thrombosis than those receiving HC, whereas in JAK2V617F-negative patients, this difference was not observed 41 .
The ANAHYDRET study compared anagrelide with HC in 259 previously untreated WHO-defined high-risk ET patients. With a total observation time of 730 patient-years, no significant difference between anagrelide and HC groups was observed regarding incidences of major and minor arterial and venous thrombosis, severe and minor bleeding, or rates of drug discontinuation. Anagrelide and HC showed a similar plateletlowering effect at six months and afterwards. Decrease of hemoglobin levels and cardiovascular side effects were more frequently observed in the anagrelide group, whereas mucocutaneous abnormalities were higher in the HC group. The rate of major clinical events was 3.3% per patient-year in the anagrelide group and 3.4% in the HC . This is the approved indication in Europe whereas in USA anagrelide can be prescribed as first-line treatment of thrombocytosis associated to myeloproliferative neoplasms. The most frequent side effects of anagrelide are headache, tachycardia, palpitations, diarrhea, and fluid retention that may lead to discontinuation in 10%-40% of patients 43 .
In my clinical practice I always inform the patient about these side effects before starting treatment, providing some practical tips as splitting the total daily dose and emphasizing that many of these effects usually decrease over time. In the small group of high-risk ET patients younger than 40 years needing cytoreduction, I also discuss the feasibility of using anagrelide as first-line therapy in an off-label use. The absence of leukemogenic effect often determines patient's preference to this therapeutic alternative when compared to HC 44 .
A general philosophy in the cytoreductive treatment strategy of ET is to normalize the platelet count, but no specific threshold (<400, <600x10 9 /L) has been demonstrated to be more protective against thrombosis 45 . However, most clinicians agree to use a normal platelet count target when treating a patient with history of thrombosis. When the patient shows toxicity or serious side effects to cytoreductive treatment, relaxing the platelet count to <600x10 9 /L may be justified 46 . A matter of debate is the need to treat an increased leukocyte count. Leukocytosis at diagnosis has been associated to inferior thrombosis-free survival in ET patients 47, 48 . In addition, lack of control of the leukocyte count during cytoreductive treatment of ET patients has been correlated with increased risk of hemorrhage and thrombosis, as well as lack of control of thrombocytosis has been related to increased bleeding 49 .
As the clinical benefit of strictly controlling this parameter is not yet established, there is no formal recommendation to initiate cytoreductive treatment based on this feature alone.
Management of patients resistant to or intolerant of hydroxycarbamide
Approximately 20% of ET patients develop resistance or intolerance to HC 50 . The ELN proposed a set of criteria to define resistance/intolerance criteria to HC in order to make decisions about when to switch to second-line treatment options 51 (Table 2) . A retrospective study of 166 ET patients treated with HC for a median of 4.5 years showed that 20% of patients met at least one criterion for resistance or intolerance.
The best discriminating criterion of the appearance of resistance to HC was anemia 
P=0.01).
With a median follow-up of two years, the probability of survival at two years was 85% and the probability of thrombosis 11%. Transformation to AL/MDS was observed in three patients 52 .
With regard to PV, roughly 16-24% of PV patients treated with HC develop resistance/intolerance to HC 53 . Similarly as in ET the ELN has produced a series of criteria for defining this clinical situation 54 (Table 3) . Briefly, these criteria include the need for venesections to keep Hct <45%, the presence of leukocytosis and thrombocytosis, and failure to control spleen size or spleen-related symptoms after three months of ≥2 g/day of HC. Additional criteria of resistance/intolerance include the appearance of cytopenia/s at the lowest dose of HC required to achieve any type of response, or the appearance of extrahematologic toxicity. In a retrospective cohort of 261 PV patients treated with HC, resistance and intolerance to HC occurred in 11%
and 13% of patients, respectively. With a median duration of treatment of 4.4 years and a median follow-up of 7 years, extrahematological toxicity (13%) and cytopenia (9%)
were the most frequent categories defining intolerance and resistance, respectively.
Patients fulfilling the ELN criteria for resistance, including those with cytopenia, had a 6.8-fold higher risk of hematologic transformation, and a significant shorter survival than patients not developing resistance. Although being a reason to switch to secondline therapy, intolerance did not entail any prognostic significance 53 . In a registry-based study of 890 patients with PV treated with HC, cytopenia at the lowest dose needed to achieve a response was an independent risk factor for transformation to AL and MF 55 .
In conclusion, the presence of cytopenia not dose-related in a PV patient treated with HC is the most clinically relevant criterion associated with a worse survival and should alert the clinician about myeloid transformation.
Recently, the JAK1/2 inhibitor ruxolitinib has been approved by the FDA and the EMA for the treatment of PV patients with inadequate response/resistant or intolerant to HC based on the results of phase 2 and phase 3 trials 56, 57 . The randomized phase 3 clinical study (RESPONSE trial) of ruxolitinib versus best available therapy (BAT) demonstrated that in PV patients with an inadequate response or with unacceptable side effects to HC, ruxolitinib was superior to standard therapy in controlling the Hct, reducing the spleen volume, and improving symptoms associated with PV. In brief, 222
patients were randomly assigned to receive ruxolitinib (n=110) or BAT (n=112). The primary endpoint was a composite of both Hct control between weeks 8 to 32 and at least a 35% reduction in spleen volume at week 32, as assessed by MRI imaging. The combined end point was achieved in 21% of the patients in the ruxolitinib group versus 1% of those in the standard-therapy group (P<0.001). Hematocrit control was achieved in 60% of patients receiving ruxolitinib and 20% of those receiving standard therapy;
38% and 1% of patients in the two groups, respectively, had at least a 35% reduction in spleen volume. In the ruxolitinib arm, the probability of maintaining the primary response for at least 80 weeks from time of response was 92%, and the probability of maintaining Hct control was 97% at week 48 and 87% at week 80. A complete hematologic remission was achieved in 24% of patients in the ruxolitinib group and in 9% of those in the standard-therapy group (P=0.003); 49% versus 5% had at least a 50% reduction in the total symptom burden score at week 32. Improvement was prominent in the cytokine symptom (fatigue, itching and night-sweats) and splenomegaly (abdominal discomfort) symptom clusters. The most frequent reported nonhematologic adverse events were headache, diarrhea, and fatigue, with very few patients presenting grade 3-4 toxicity. In the ruxolitinib group, grade 3 or 4 anemia occurred in 2% of patients, and grade 3 or 4 thrombocytopenia occurred in 5%; the corresponding percentages in the standard-therapy group were 0% and 4%. Herpes zoster infection was reported in 6% of patients in the ruxolitinib group and 0% of those in the standard-therapy group (grade 1 or 2 in all cases). Thromboembolic events occurred in one patient receiving ruxolitinib and in six patients receiving standard therapy 57 . In spite of the effectiveness of ruxolitinib to control symptoms, hematocrit and spleen size, only long-term follow-up will confirm or not its ability to achieve clinically relevant end-points in PV such as the decrease of vascular complications and transformation to myelofibrosis, that is, the possibility to modify the natural history of the disease.
Management of disease transformation
In PV and ET patients transformation to myelofibrosis (post-PV, post-ET MF) must be suspected when progressive splenomegaly, anemia and leukoerythroblastic picture appear during clinical follow-up. Overall, the clinical, laboratory, and histological features of post-PV/ET MF are alike to those of primary myelofibrosis (PMF) patients.
Consequently, treatment should follow the same principles as for patients with PMF.
This subject is beyond the scope of this paper and excellent reviews concerning this . In those patients candidates only to palliative treatment, oral mercaptopurine and transfusion support is a wise approach. has not shown a strong correlation of mutational status and pregnancy complications.
Management of unusual and risk situations
However, the presence of JAK2V617F mutation was associated with late pregnancy losses, whereas the presence of CALR mutations was associated with a trend to a better outcome 64 .
In ET females receiving cytoreduction who desire to be pregnant, cytoreductive treatment must be stopped at least three months before conception (wash-out period).
High-risk pregnancy is defined when the patient has suffered previous maternal thrombotic or hemorrhagic events and/or previous severe pregnancy complications 65 .
Treatment should always be adjusted to pregnancy risk. In low-risk pregnancy lowdose ASA throughout pregnancy is a practical and reasonable option, although is not evidence-based. In high-risk pregnancies additional treatment including IFN-α plus low molecular weight heparin (LMWH) is recommended 63, 66 . During the postpartum period strict control of platelet count and Hct is required and LMWH at prophylactic doses is always indicated for at least six weeks postpartum, irrespective of the risk group.
Definitely, the management of pregnancy in ET must be carried out by a multidisciplinary team, including an obstetrician experienced in high-risk pregnancies. 
Surgery

